BioWorld

June 4, 2008

Vertex Sells Royalty Rights to HIV Inhibitors for $160 Million

Vertex Pharmaceuticals Inc. is unloading two HIV protease inhibitors it helped develop in a $160 million deal with GlaxoSmithKline plc in which it agreed to sell rights to future royalties for Lexiva and Agenerase. (BioWorld Today) Read More

New Data Show Avant's Vaccine Doubles Survival in Brain Cancer

IRX Brings in $25M to Advance Lead Cancer Compound, IRX-2

NewCo News: NexBio Cuts Off Influenza Virus from its Entry Route

Gen-Probe Makes Counterbid for Diagnostics Firm Innogenetics

Other News To Note

ASCO Roundup: Incyte Slips on Myelofibrosis Data; ImmunoGen Falls, Too

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 18, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 16, 2026

Gene replacement rescues autism-related phenotypes in mice

BioWorld Science

Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...

For clonal hematopoiesis, epigenetics can be in driver’s seat

BioWorld Science

Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...

Illustration of amyloid plaques in Alzheimer's disease

Elixiron’s enrupatinib shows upbeat interim phase II AD results

BioWorld

Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...